Veradermics CTO sells 43.5K shares after option
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Veradermics, Inc (MANE) reported that its Chief Technical Officer, Timothy August Durso, exercised stock options for 3,452 shares of Common Stock at an exercise price of $12.19 per share and on the same date sold an aggregate of 43,500 Common shares in multiple open-market transactions at weighted average prices ranging from about $106.71 to $111.28 per share. The option was fully vested and exercisable, and the transactions were made pursuant to a Rule 10b5-1 trading plan.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
7 txns
Insider
Durso Timothy August
Role
Chief Technical Officer
Sold
43,500 shs ($4.69M)
Approx. gross sale proceeds
$4.69M
Approx. exercise cost
$42K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F5 | 3,452 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,452 | $12.19 | $42K |
| Sale | Common Stock F1 | 7,918 | $106.71 | $845K |
| Sale | Common Stock F2 | 16,306 | $107.52 | $1.75M |
| Sale | Common Stock F3 | 16,767 | $108.38 | $1.82M |
| Sale | Common Stock F4 | 2,348 | $109.34 | $257K |
| Sale | Common Stock | 161 | $111.28 | $18K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 78,142 shares (Direct)
Footnotes (5)
- F1. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.25 to $106.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.00 to $107.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $108.00 to $108.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $109.00 to $109.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5. This option is fully vested and exercisable as of the date hereof.
Key Figures
Options Exercised: 3,452 shares
Option Exercise Price: $12.19 per share
Total Shares Sold: 43,500 shares
+5 more
8 metrics
Options Exercised
3,452 shares
Stock Option (Right to Buy) exercised into Common Stock on 2026-08-17
Option Exercise Price
$12.19 per share
Exercise price for 3,452-share stock option
Total Shares Sold
43,500 shares
Aggregate Common Stock sold on 2026-08-17
Sale Price Tranche 1
$106.71 per share
Weighted average price for 7,918-share sale, range $106.25–$106.99
Sale Price Tranche 2
$107.52 per share
Weighted average price for 16,306-share sale, range $107.00–$107.99
Sale Price Tranche 3
$108.38 per share
Weighted average price for 16,767-share sale, range $108.00–$108.99
Sale Price Tranche 4
$109.34 per share
Weighted average price for 2,348-share sale, range $109.00–$109.96
Sale Price Tranche 5
$111.28 per share
Price for 161-share sale of Common Stock
Key Terms
Stock Option (Right to Buy), derivative security, weighted average price, Rule 10b5-1 trading plan
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Rule 10b5-1 trading plan regulatory
"transactions were made pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did MANE’s CTO report on this Form 4?
The CTO of Veradermics, Inc (MANE) reported exercising 3,452 stock options at $12.19 per share and selling 43,500 Common shares on August 17, 2026. The sales occurred in multiple open-market trades at various weighted average prices above $106 per share.
What stock option exercise did the Veradermics (MANE) CTO report?
The CTO exercised a Stock Option (Right to Buy) covering 3,452 shares of Veradermics (MANE) Common Stock at an exercise price of $12.19 per share. The option was fully vested and exercisable as of the transaction date, and was then fully exercised.
Were the MANE insider sales made under a Rule 10b5-1 trading plan?
Yes. The filing indicates the transactions were made pursuant to a Rule 10b5-1 trading plan. Such plans pre-arrange trade timing and amounts, which can reduce the informational value of transaction timing about the insider’s current view of Veradermics (MANE).
What was the overall direction of the MANE insider’s reported trades?
Overall activity on this Form 4 reflects a net sale of 43,500 shares of Veradermics (MANE) Common Stock. Although 3,452 options were exercised into shares, the insider’s reported open-market dispositions far exceeded the acquired amount, resulting in net selling.
AI-generated analysis. How Rhea-AI works. Not financial advice.
